Human CXCR5+PD‐1+ CD8 T cells in healthy individuals and patients with hematologic malignancies
Authors:
- Tom HoflandTHTom Hofland
- Anne W.J. MartensAMAnne W.J. Martens
- Jaco A.C. van BruggenJBJaco A.C. van Bruggen
- Sjoerd SchettersSSSjoerd Schetters
- Ester B.M. RemmerswaalEREster B.M. Remmerswaal
- Frederike J. BemelmanFBFrederike J. Bemelman
- Mark‐David LevinMLMark‐David Levin
- Adriaan D. BinsABAdriaan D. Bins
- Eric ElderingEEEric Eldering
- Arnon P. KaterAKArnon P. Kater
- Sanne H. ToninoSTSanne H. Tonino
Open Access
- 24 October 2020
- journal article
- research article
- Published by Wiley in European Journal of Immunology
- Vol. 51 (3) , 703-713
Abstract
Immune checkpoint blockade (ICB) has revolutionized cancer therapy, but varying response rates illustrate the need for biomarkers of response. Studies in mice have identified a subset of CD8 T cells that is essential for response to PD‐1 ICB. These CD8 T cells co‐express CXCR5, PD‐1 and Tcf1, and provide effector T cells upon PD‐1 ICB. It is unknown whether similar T cells play a role in PD‐1 ICB in humans.We studied human peripheral blood and lymph nodes (LNs) for the frequency, phenotype, and functionality of CXCR5+PD‐1+ CD8 T cells. We find that CXCR5+PD‐1+ CD8 T cells are memory‐like cells, express Tcf1, and lack expression of effector molecules. CXCR5+PD‐1+ CD8 T cells produce cytokines upon stimulation, but have limited proliferative capacity. We studied patients with hematologic malignancies with varying response rates to PD‐1 ICB. Specifically in chronic lymphocytic leukemia, in which PD‐1 ICB does not induce clinical responses, CXCR5+PD‐1+ CD8 T cells show loss of the memory phenotype and increased effector differentiation.In conclusion, we identified CXCR5+PD‐1+ CD8 T cells in human peripheral blood and LN, which could play a similar role during PD‐1 ICB. Future studies should analyze CXCR5+PD‐1+ CD8 T cells during PD‐1 ICB and their importance for therapeutic response.Keywords
This publication has 31 references indexed in Scilit:
- Nivolumab plus Ipilimumab in Advanced MelanomaNew England Journal of Medicine, 2013
- Mutational heterogeneity in cancer and the search for new cancer-associated genesNature, 2013
- T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine productionBlood, 2013
- Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancerBlood, 2012
- Histo-Cytometry: A Method for Highly Multiplex Quantitative Tissue Imaging Analysis Applied to Dendritic Cell Subset Microanatomy in Lymph NodesImmunity, 2012
- Human virus-specific effector-type T cells accumulate in blood but not in lymph nodesBlood, 2012
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant nichesBlood, 2008
- CXCR5+ CCR7– CD8 T cells are early effector memory cells that infiltrate tonsil B cell folliclesEuropean Journal of Immunology, 2007
- Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cellsJournal of Clinical Investigation, 2005